Clinical trials: Fallopian Tubes Cancer
Ovarian Cancer, Fallopian Tube Cancer
Choices About Genetic Testing And Learning Your Risk With Smart Technology
This study seeks to enhance genetic education and increase the uptake of genetic testing for hereditary cancer risk among cancer survivors.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer
- Trial name
- CATALYST (NCT06184867)
- Testing
- Relational Agent (RA), Enhanced Usual Care (EUC)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Cervical Cancer, Endometrial Cancer
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
RATIONALE: To improve strategies for detection and prevention of early-stage disease. PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer…
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
- Trial name
- NCT00005095
- Testing
- Ca-125, screening questionnaire administration, Surgery
- Where
- United States
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Ovarian Cancer, Fallopian Tube Cancer
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Phase I study to evaluate intraperitoneal carboplatin along with weekly intravenous paclitaxel and bevacizumab in order to establish a tolerable dose and define the toxicity of this regimen in previously untreated patients with…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, No Prior Chemotherapy
- Trial name
- NCT01220154
- Testing
- Paclitaxel, Carboplatin, Bevacizumab
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- David O'Malley
Ovarian Cancer, Fallopian Tube Cancer
Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)
This study evaluates whether the adoption of the RADAR dosing strategy could further reduce treatment related toxicities improving the safety profile of niraparib.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- Newton (NCT03891576)
- Testing
- Niraparib
- Where
- 12 sites in Germany, Italy
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Breast Carcinoma, Deleterious CDH1 Gene Mutation
Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives
This trial collects information about factors that affect communication of genetic test results, decision-making, and access to genetic testing in women with hereditary gynecological cancers.
- Conditions
- Breast Carcinoma, Deleterious CDH1 Gene Mutation, Deleterious DICER1 Gene Mutation, Deleterious SMARCA4 Gene Mutation
- Trial name
- NCT04257045
- Testing
- Interview, Questionnaire Administration, Survey Administration
- Where
- 2 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer
The purpose of this study is to learn about possible changes in brain anatomy and function, and in thinking abilities, such as memory skills, in patients with ovarian cancer who receive treatment with chemotherapy.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- Trial name
- NCT01591772
- Testing
- Neuroimaging & Neuropsychological Evaluation
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Ovarian Carcinoma
Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage
Screening programs for high-grade ovarian carcinoma failed to reduce disease-specific mortality, since they do not offer early enough detection of the disease.
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- BEDOCA (NCT03150121)
- Testing
- Uterine lavage, Blood sample, Uterine lavage catheter
- Where
- 4 sites in Israel
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Fallopian Tube Cancer, Peritoneal Cavity Cancer
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and pegylated liposomal doxorubicin hydrochloride (PLD) work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Conditions
- Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT01281514
- Testing
- everolimus, carboplatin, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer
A Survivorship Care Plan for Gynaecological Cancer Patients
After treatment women surviving gynaecological cancer may experience lateeffects and longterm challenges specific to their disease and treatment resulting in functional deficits and a reduction in societal integration (Yabroff et…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer, Endometrial Cancer, Esophageal Cancer
- Trial name
- NCT01582906
- Where
- United Kingdom
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer
Validation of a Nutrition Screening Tool
The objective of this study is to evaluate the sensitivity and specificity of two nutrition screening tools to identify inpatients with malnutrition or at risk of malnutrition.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer, Endometrial Cancer, Esophageal Cancer
- Trial name
- NCT01851928
- Where
- United Kingdom
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust